NCT05131997

A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Administrated AD-221 and AD-221A in Patients With Primary Hypercholesterolemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 290 (actual)
• Sponsor: Addpharma Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A

Detailed description

The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A in patients with primary hypercholesterolemia

Conditions

• Primary Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	AD-221	PO, Once daily(QD), 8 weeks
DRUG	AD-221A	PO, Once daily(QD), 8 weeks
DRUG	AD-221B	PO, Once daily(QD), 8 weeks
DRUG	AD-221C	PO, Once daily(QD), 8 weeks

Timeline

• Start date: 2021-11-16
• Primary completion: 2022-06-08
• Completion: 2022-06-08
• First posted: 2021-11-23
• Last updated: 2022-07-20

Locations

1 site across 1 country: South Korea